Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation
- PMID: 20520605
- DOI: 10.1038/clpt.2010.54
Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation
Erratum in
- Clin Pharmacol Ther. 2010 Sep;88(3):424
Abstract
In controlled ovarian stimulation (COS), a single subcutaneous dose of corifollitropin alfa is used to initiate and sustain multifollicular growth for 7 days. The objective of this study was to determine the optimal dose of corifollitropin alfa. A pharmacokinetic model was developed to describe the time profile of corifollitropin alfa concentrations. Multiple parameters reflecting ovarian response were included in a pharmacokinetic-pharmacodynamic (PK-PD) model framework. An early decline in serum inhibin B was shown to be a sensitive marker for COS failure. Simulations were performed to select the lowest corifollitropin alfa dose that would result in a minimal cancellation rate: 100 microg for a group of women weighing <or=60 kg and 150 microg for a group of women weighing >60 kg. With these doses, the predicted mean number of oocytes per started COS cycle was similar in the two groups, i.e., 12.1 and 13.2, respectively. The selected doses were tested in prospective clinical trials and were proven to be adequate.
Similar articles
-
A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation.Hum Reprod. 2008 Nov;23(11):2484-92. doi: 10.1093/humrep/den288. Epub 2008 Aug 6. Hum Reprod. 2008. PMID: 18684735 Clinical Trial.
-
Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response.Reprod Biomed Online. 2011 Aug;23(2):150-9. doi: 10.1016/j.rbmo.2011.04.002. Epub 2011 Apr 15. Reprod Biomed Online. 2011. PMID: 21665541 Review.
-
Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency.Hum Reprod Update. 2009 May-Jun;15(3):309-21. doi: 10.1093/humupd/dmn065. Epub 2009 Jan 30. Hum Reprod Update. 2009. PMID: 19182099 Review.
-
Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trial.Fertil Steril. 2010 Oct;94(5):1922-4. doi: 10.1016/j.fertnstert.2009.12.070. Epub 2010 Feb 10. Fertil Steril. 2010. PMID: 20149360 Clinical Trial.
-
Corifollitropin alfa, a long-acting follicle-stimulating hormone agonist for the treatment of infertility.Curr Opin Investig Drugs. 2009 Apr;10(4):372-80. Curr Opin Investig Drugs. 2009. PMID: 19337959 Review.
Cited by
-
Population Pharmacokinetic Modelling of FE 999049, a Recombinant Human Follicle-Stimulating Hormone, in Healthy Women After Single Ascending Doses.Drugs R D. 2016 Jun;16(2):173-80. doi: 10.1007/s40268-016-0129-9. Drugs R D. 2016. PMID: 27003895 Free PMC article. Clinical Trial.
-
Long-acting FSH versus daily FSH for women undergoing assisted reproduction.Cochrane Database Syst Rev. 2015 Jul 14;2015(7):CD009577. doi: 10.1002/14651858.CD009577.pub3. Cochrane Database Syst Rev. 2015. PMID: 26171903 Free PMC article.
-
The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist.Int J Womens Health. 2011;3:243-55. doi: 10.2147/IJWH.S15002. Epub 2011 Aug 8. Int J Womens Health. 2011. PMID: 21892335 Free PMC article.
-
Impact of patient characteristics on the pharmacokinetics of corifollitropin alfa during controlled ovarian stimulation.Br J Clin Pharmacol. 2016 Jul;82(1):74-82. doi: 10.1111/bcp.12939. Epub 2016 May 31. Br J Clin Pharmacol. 2016. PMID: 26991902 Free PMC article.
-
Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis.J Ovarian Res. 2015 Jun 3;8:33. doi: 10.1186/s13048-015-0160-4. J Ovarian Res. 2015. PMID: 26036214 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources